Accendra Health Reports 10.1% Revenue Decline to $613.2 Million in Q2 2026

Accendra Health, Inc. reported a net revenue of $613.2 million for the three months ended June 30, 2026, a decrease of 10.1% from $681.9 million in the same period last year. For the first half of 2026, the company generated $1.24 billion in revenue, down 8.5% from $1.36 billion in the prior year. The decline in revenue was primarily attributed to a significant reduction in sales from terminated contracts with a commercial payor, which accounted for approximately $81 million of the revenue drop. The company also experienced increased costs, with total operating expenses for the second quarter amounting to $648.4 million, down from $721.6 million a year earlier, reflecting a decrease in selling, general, and administrative expenses.

Accendra's operating loss for the second quarter was $35.2 million, an improvement from a loss of $39.7 million in the same quarter of 2025. The loss from continuing operations for the quarter was $89.1 million, compared to $83.8 million in the previous year. The company reported a basic loss per share of $1.16 for the second quarter of 2026, slightly higher than the $1.09 loss per share reported in the same period last year. The financial results were impacted by increased acquisition-related charges and intangible amortization, which rose to $29.2 million from $13.9 million in the prior year.

In terms of strategic developments, Accendra completed a significant Balance Sheet Optimization Transaction in June 2026, which involved the exchange and extension of a substantial portion of its debt. This included the issuance of new senior secured notes due in 2032 and 2033, replacing older unsecured notes. The transaction resulted in a loss on modification and extinguishment of debt amounting to $17 million. Additionally, the company has been managing the transition following the sale of its Products and Healthcare Services business, which was completed at the end of 2025, and has incurred related exit and realignment charges.

Operationally, Accendra's cash and cash equivalents decreased significantly to $7.7 million as of June 30, 2026, down from $282 million at the end of 2025. The company reported an increase in accounts receivable, which rose to $120.1 million, reflecting a 25.2% increase from the previous period. The company’s employee headcount remained stable, with no significant changes reported. Looking ahead, Accendra expects to continue focusing on optimizing its operations and managing its debt while navigating the challenges posed by market conditions and the ongoing transition from its previous business structure. The company remains committed to enhancing its financial performance and operational efficiency in the coming quarters.